# US 2022/0031687 A1 · Synergic pharmaceutical combination of a leukotriene-receptor antagonist and an inverse agonist of histamine hi

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031687 A1
- Document ID: US20220031687A1
- Status: Published application
- Kind: A1
- Application number: 17/280,049
- Filed: 2019-09-20
- Published: 2022-02-03
- Earliest claimed: 2018-09-26
- Assignees: Federico Amezcua Amezcua; Carlos Amezcua Amezcua
- Inventors: Patricia del Carmen Garcia Armenta; Jose Alonso Chavez Garcia
- Web page: https://patentgrep.com/patent/US20220031687A1

## CPC

- A61K 31/47: Quinolines; Isoquinolines
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0043: {Nose}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/4535: containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention refers to a pharmaceutical combination comprising the synergic combination of a leukotriene-receptor antagonist such as the active principle montelukast and pharmaceutically acceptable salts thereof, and an histamine H1 inverse agonist such as the active principle ketotifen and pharmaceutically acceptable salts thereof, formulated with pharmaceutically acceptable excipients and/or carriers and/or additives, in a single dosing unit to be administered orally, transdermally or in devices for oral or nasal inhalation, indicated for the treatment of an atopic disease such as asthma, allergic rhinitis and atopic dermatitis.

## Claims

### Claim 1

A synergic pharmaceutical combination comprising:
i. a leukotriene-receptor antagonist agent and/or pharmaceutically acceptable salts thereof,
ii. a histamine H1 inverse agonist agent and/or pharmaceutically acceptable salts thereof,
iii. a pharmaceutically acceptable carrier and/or excipient and/or additive, formulated as a single dosing unit for oral, nasal, intravenous, or intramuscular administration, for treatment and control of an atopic disease in a mammal comprising asthma, allergic rhinitis and atopic dermatitis.

### Claim 2 (depends on 1)

The combination of claim 1 wherein the leukotriene-receptor antagonist agent is montelukast or pharmaceutically acceptable salts thereof in a concentration of approximately 0.01 mg/kg to approximately 1000 mg/kg.

### Claim 3 (depends on 1)

The combination of claim 1 wherein the histamine H1 inverse agonist agent is ketotifen or pharmaceutically acceptable salts thereof in a concentration of approximately 0.01 mg/kg to approximately 1000 mg/kg.

### Claim 4 (depends on 1)

The combination of claim 1 wherein the leukotriene-receptor antagonist agent is montelukast or pharmaceutically acceptable salts thereof in a concentration of approximately 0.01 mg/kg to approximately 1000 mg/kg, and the histamine H1 inverse agonist agent is agent ketotifen or pharmaceutically acceptable salts thereof in a concentration of approximately 0.01 mg/kg to approximately 1000 mg/kg.

### Claim 5 (depends on 1)

The combination of claim 1 wherein the single dosing unit is administered orally as a capsule, tablet, lozenge, sublingual tablet, granules, caplet, suspension or solution; or wherein the single dosing unit is an intramuscularly or intravenously injectable formulation; or wherein the single dosing unit is formulated for use in oral or nasal inhalation devices.

### Claim 6 (depends on 1)

The combination of claim 1 wherein the mammal is a human.

### Claim 7

A method of treating an atopic disease comprising administering to mammals suffering the disease an effective amount of a combination of at least one leukotriene-receptor antagonist agents and at least one histamine H1 inverse agonist agents.

### Claim 8 (depends on 7)

The method of claim 7 wherein the combination is administered orally, nasally, intramuscularly, intravenously, or a combination thereof.

### Claim 9 (depends on 8)

The method according to claim 8 wherein the leukotriene-receptor antagonist agents is montelukast or pharmaceutically acceptable salts thereof administered in an amount of approximately 0.01 mg to approximately 1000 mg/day, and the histamine H1 inverse agonist agents is ketotifen or pharmaceutically acceptable salts thereof administered in an amount of approximately 0.01 mg to approximately 1000 mg/day.

### Claim 10 (depends on 7)

The method of claim 7 wherein the leukotriene-receptor antagonist agent is montelukast or pharmaceutically acceptable salts thereof, and the histamine H1 inverse agonist agent is agent ketotifen or pharmaceutically acceptable salts thereof.

### Claim 11 (depends on 10)

The method of claim 10 wherein the montelukast or pharmaceutically acceptable salts thereof is in a concentration of approximately 0.01 mg/kg to approximately 1000 mg/kg, and ketotifen or pharmaceutically acceptable salts thereof is in a concentration of approximately 0.01 mg/kg to approximately 1000 mg/kg.

### Claim 12 (depends on 7)

The method of claim 7 wherein the atopic disease is asthma, allergic rhinitis, or atopic dermatitis.

### Claim 13

A method of treating asthma comprising administering to mammals suffering from asthma an effective amount of a combination of at least one leukotriene-receptor antagonist agents and at least one histamine H1 inverse agonist agents.

### Claim 14 (depends on 13)

The method of claim 13 wherein the combination is administered orally, nasally, intramuscularly, intravenously, or a combination thereof.

### Claim 15 (depends on 14)

The method of claim 14 wherein the leukotriene-receptor antagonist agent is montelukast or pharmaceutically acceptable salts thereof, and the histamine H1 inverse agonist agent is agent ketotifen or pharmaceutically acceptable salts thereof.

### Claim 16 (depends on 15)

The method of claim 15 wherein the montelukast or pharmaceutically acceptable salts is administered in a concentration of approximately 0.01 mg/kg to approximately 1000 mg/kg, and the histamine H1 inverse agonist agent is agent ketotifen or pharmaceutically acceptable salts administered in a concentration of approximately 0.01 mg/kg to approximately 1000 mg/kg.
